Segment Disclosure

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Disclosure

12.Segment disclosure:

The Company operates as a single reportable segment dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need. The Company has no products approved for sale and has not generated any revenue from product sales. The Company’s Chief Executive Officer acts as the chief operating decision maker and manages the Company’s operations on a consolidated basis, using net loss to assess performance and allocate resources. The accounting policies of the segment are the same as those disclosed in the Company’s 2024 Annual Report on Form 10-K, with the exception of the policy described in note 3. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets, with a majority of these assets located in the United States.

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Three Months Ended March 31,
	2025			2024
Collaboration revenue	$	7,500		$	—
Less:
Direct external research and development costs
Azetukalner		31,501			23,213
Pre-clinical, discovery and other programs		4,967			3,661
Personnel-related expenses		22,640			14,854
Stock-based compensation expense		12,174			9,400
Other research and development costs		3,425			3,014
Other general and administrative costs		5,531			4,899
Interest income		(8,083	)		(11,355	)
Other segment items(1)		392			245
Net loss	$	(65,047	)	$	(47,931	)

(1)Other segment items include foreign exchange gain and income tax expense.